Novel mRNA Nanoparticles Successfully Target and Slow Glioblastoma Growth in Mice
Researchers have developed an innovative mRNA nanoparticle therapy utilizing mannose coatings to cross the blood-brain barrier and precisely target aggressive glioblastoma brain tumors in mice.
Glioblastoma remains one of the most aggressive and lethal forms of brain cancer, originating from glial cells that support neurons. Despite aggressive treatments, median survival is severely limited, prompting researchers worldwide to seek innovative therapeutic approaches. A new study led by cancer researcher Oleh Taratula at Oregon State University introduces an experimental treatment utilizing therapeutic mRNA molecules to target cancer cells.
The research addresses two major obstacles in treating glioblastoma: penetrating the blood-brain barrier (BBB)—a dense cellular layer protecting the brain from pathogens—and ensuring the treatment specifically targets cancer cells while sparing healthy tissue. Traditional methods encapsulate mRNA in lipid nanoparticles to protect it from degradation, but these particles struggle to cross the blood-brain barrier and lack precise tumor targeting.
To overcome these limitations, the research team exploited the Glucose transporter 1 (GLUT1) protein, which facilitates sugar entry into cells and is abundantly expressed on both the blood-brain barrier and glioblastoma cells. By coating lipid nanoparticles with mannose sugar molecules, the researchers enabled the nanoparticles to bind to GLUT1, facilitating successful crossing of the blood-brain barrier and subsequent entry into tumor cells.
Following extensive chemical development and optimization, the researchers tested the nanoparticles in murine models. The engineered nanoparticles successfully crossed the blood-brain barrier and accumulated within brain tissue. Furthermore, injections in mice with glioblastoma tumors demonstrated that within six hours, mRNA accumulation in the tumor was double that of surrounding healthy brain tissue, highlighting exceptional targeting precision.
Finally, the team tested the therapeutic efficacy by loading the nanoparticles with mRNA encoding the PTEN tumor suppressor protein, which typically loses function in glioblastoma. Administering four doses to mice significantly slowed tumor progression, maintained stable body weight, and extended survival compared to control groups. Although further preclinical and clinical studies are required to confirm safety and efficacy in humans, this innovative approach offers a promising horizon for combating aggressive brain tumors.
